Full Text of HR1021 102nd General Assembly
HR1021 102ND GENERAL ASSEMBLY |
| | HR1021 | | LRB102 29752 LAW 41817 r |
|
| 1 | | HOUSE RESOLUTION
| 2 | | WHEREAS, Cardiovascular disease (CVD) is the leading cause | 3 | | of death in the United States, and African Americans have the | 4 | | highest overall mortality rate from coronary heart disease | 5 | | (CHD) of any ethnic group in the United States, particularly | 6 | | in out-of-hospital deaths and at especially younger ages; and
| 7 | | WHEREAS, According to the U.S. Census Bureau, | 8 | | approximately 21 million patients have been diagnosed with | 9 | | atherosclerotic cardiovascular disease (ASCVD) in the United | 10 | | States and are at risk of experiencing a cardiovascular event; | 11 | | and
| 12 | | WHEREAS, The Mayo Clinic states that ASCVD is linked to | 13 | | the build-up of cholesterol in the arteries and the risk of | 14 | | associated events can be modified by lowering low-density | 15 | | lipoprotein cholesterol (LDL-C); and
| 16 | | WHEREAS, In 2016, nearly 70 million adults in the United | 17 | | States had higher than recommended LDL-C levels; and
| 18 | | WHEREAS, Approximately 43.1 million people in the United | 19 | | States are currently being treated with lipid-lowering | 20 | | therapies to manage cardiovascular risk; and
|
| | | HR1021 | - 2 - | LRB102 29752 LAW 41817 r |
|
| 1 | | WHEREAS, Only 20% of people with ASCVD who are taking | 2 | | statins, one of the leading lipid-lowering therapies, actually | 3 | | achieve healthy levels of LDL-C; and
| 4 | | WHEREAS, The American Heart Association has indicated the | 5 | | total direct and indirect cost of ASCVD in the U.S. was $555 | 6 | | billion in 2016 with it being projected to climb to $1.1 | 7 | | trillion by 2035; and
| 8 | | WHEREAS, In Illinois, 776,900 adults have been told by a | 9 | | health professional that they had angina, a stroke, a heart | 10 | | attack, or coronary heart disease, which are some of the | 11 | | manifestations of ASCVD; 363,500 adults have reported | 12 | | experiencing a heart attack in their lifetime and 293,300 | 13 | | adults have reported experiencing a stroke in their lifetime; | 14 | | 13,484 people had ASCVD as an underlying cause of death; and
| 15 | | WHEREAS, Illinois spends an estimated $4.59 billion | 16 | | dollars on direct medical expenses for ASCVD care each year; | 17 | | therefore, be it
| 18 | | RESOLVED, BY THE HOUSE OF REPRESENTATIVES OF THE ONE | 19 | | HUNDRED SECOND GENERAL ASSEMBLY OF THE STATE OF ILLINOIS, that | 20 | | we urge state agencies to expand comprehensive cardiovascular | 21 | | screening programs to allow for earlier identification of | 22 | | patients at risk of cardiovascular events; and be it further
|
| | | HR1021 | - 3 - | LRB102 29752 LAW 41817 r |
|
| 1 | | RESOLVED, That we urge state agencies to explore ways to | 2 | | collaborate with federal and national agencies and | 3 | | organizations to establish or expand comprehensive | 4 | | cardiovascular screening programs; and be it further
| 5 | | RESOLVED, That we urge an update of the State's | 6 | | cardiovascular plan to accelerate quality improvements in the | 7 | | care rendered to these patients such that screening, | 8 | | treatment, monitoring, and improved health outcomes are | 9 | | achieved; and be it further
| 10 | | RESOLVED, That we support the creation of policies to | 11 | | decrease the rising number of deaths of Americans as a result | 12 | | of ASCVD; and be it further
| 13 | | RESOLVED, That suitable copies be delivered to the | 14 | | Governor, the Lieutenant Governor, the Director of the | 15 | | Department of Public Health, the Director of the Department of | 16 | | Healthcare and Family Services, and the Secretary of the | 17 | | Department of Human Services.
|
|